JP2019536763A5 - - Google Patents

Download PDF

Info

Publication number
JP2019536763A5
JP2019536763A5 JP2019522993A JP2019522993A JP2019536763A5 JP 2019536763 A5 JP2019536763 A5 JP 2019536763A5 JP 2019522993 A JP2019522993 A JP 2019522993A JP 2019522993 A JP2019522993 A JP 2019522993A JP 2019536763 A5 JP2019536763 A5 JP 2019536763A5
Authority
JP
Japan
Prior art keywords
substituted
unsubstituted
compound according
formula
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019522993A
Other languages
English (en)
Japanese (ja)
Other versions
JP7236996B2 (ja
JP2019536763A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/059871 external-priority patent/WO2018089261A2/en
Publication of JP2019536763A publication Critical patent/JP2019536763A/ja
Publication of JP2019536763A5 publication Critical patent/JP2019536763A5/ja
Priority to JP2022184820A priority Critical patent/JP2023029752A/ja
Application granted granted Critical
Publication of JP7236996B2 publication Critical patent/JP7236996B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019522993A 2016-11-03 2017-11-03 インターロイキン-2誘導性t細胞キナーゼを調節する化合物及び方法 Active JP7236996B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022184820A JP2023029752A (ja) 2016-11-03 2022-11-18 インターロイキン-2誘導性t細胞キナーゼを調節する化合物及び方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662417083P 2016-11-03 2016-11-03
US62/417,083 2016-11-03
PCT/US2017/059871 WO2018089261A2 (en) 2016-11-03 2017-11-03 Compounds and methods for modulating interleukin-2-inducible t-cell kinase

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022184820A Division JP2023029752A (ja) 2016-11-03 2022-11-18 インターロイキン-2誘導性t細胞キナーゼを調節する化合物及び方法

Publications (3)

Publication Number Publication Date
JP2019536763A JP2019536763A (ja) 2019-12-19
JP2019536763A5 true JP2019536763A5 (https=) 2020-12-17
JP7236996B2 JP7236996B2 (ja) 2023-03-10

Family

ID=62109599

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019522993A Active JP7236996B2 (ja) 2016-11-03 2017-11-03 インターロイキン-2誘導性t細胞キナーゼを調節する化合物及び方法
JP2022184820A Pending JP2023029752A (ja) 2016-11-03 2022-11-18 インターロイキン-2誘導性t細胞キナーゼを調節する化合物及び方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022184820A Pending JP2023029752A (ja) 2016-11-03 2022-11-18 インターロイキン-2誘導性t細胞キナーゼを調節する化合物及び方法

Country Status (14)

Country Link
US (3) US11008314B2 (https=)
EP (1) EP3534899B1 (https=)
JP (2) JP7236996B2 (https=)
KR (1) KR102540515B1 (https=)
CN (1) CN110099684B (https=)
AU (1) AU2017358901B2 (https=)
CA (1) CA3042252C (https=)
DK (1) DK3534899T3 (https=)
ES (1) ES2926153T3 (https=)
IL (1) IL266181B2 (https=)
MX (1) MX392031B (https=)
PT (1) PT3534899T (https=)
WO (1) WO2018089261A2 (https=)
ZA (1) ZA201903071B (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9227978B2 (en) 2013-03-15 2016-01-05 Araxes Pharma Llc Covalent inhibitors of Kras G12C
JO3805B1 (ar) 2013-10-10 2021-01-31 Araxes Pharma Llc مثبطات كراس جي12سي
ES2898765T3 (es) 2015-04-10 2022-03-08 Araxes Pharma Llc Compuestos de quinazolina sustituidos y métodos de uso de los mismos
EP3356359B1 (en) 2015-09-28 2021-10-20 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
EP3356349A1 (en) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
WO2017058728A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
EP3356347A1 (en) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
KR20180081596A (ko) 2015-11-16 2018-07-16 아락세스 파마 엘엘씨 치환된 헤테로사이클릭 그룹을 포함하는 2-치환된 퀴나졸린 화합물 및 이의 사용 방법
IL266181B2 (en) * 2016-11-03 2024-04-01 Corvus Pharmaceuticals Inc Compounds and methods for modulating interleukin-2-inducible t-cell kinase
EP3573954A1 (en) 2017-01-26 2019-12-04 Araxes Pharma LLC Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
WO2018140513A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer
US11136308B2 (en) 2017-01-26 2021-10-05 Araxes Pharma Llc Substituted quinazoline and quinazolinone compounds and methods of use thereof
WO2018140599A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc Benzothiophene and benzothiazole compounds and methods of use thereof
JP7327802B2 (ja) 2017-01-26 2023-08-16 アラクセス ファーマ エルエルシー 縮合ヘテロ-ヘテロ二環式化合物およびその使用方法
WO2018218069A1 (en) 2017-05-25 2018-11-29 Araxes Pharma Llc Quinazoline derivatives as modulators of mutant kras, hras or nras
US10745385B2 (en) 2017-05-25 2020-08-18 Araxes Pharma Llc Covalent inhibitors of KRAS
MX2021000887A (es) 2018-08-01 2021-03-31 Araxes Pharma Llc Compuestos espiroheterociclicos y metodos de uso de los mismos para el tratamiento de cancer.
CN113207291A (zh) * 2018-10-24 2021-08-03 亚瑞克西斯制药公司 2-(2-丙烯酰基-2,6-二氮杂螺[3.4]辛-6-基)-6-(1h-吲唑-4-基)苄腈衍生物及相关化合物作为用于抑制肿瘤转移的g12c突变kras蛋白的抑制剂
WO2021092240A1 (en) * 2019-11-05 2021-05-14 Dermira, Inc. Mrgprx2 antagonists for the treatment of inflammatory disorders
US12441707B2 (en) 2019-12-30 2025-10-14 Tyra Biosciences, Inc. Indazole compounds
US20230226196A1 (en) * 2020-06-23 2023-07-20 Dana-Farber Cancer Institute, Inc. Compounds for targeted degradation of interleukin-2-inducible t-cell kinase and methods of use
CN114605404B (zh) * 2022-03-23 2024-01-05 合肥美诺医药有限公司 一种新型含噻唑类化合物、中间体及其应用
CN114621213B (zh) * 2022-03-23 2023-12-08 合肥美诺医药有限公司 含噻唑类化合物及其中间体与应用
US20250213587A1 (en) * 2022-04-05 2025-07-03 Corvus Pharmaceuticals, Inc. Itk inhibitors for increasing th1 cell activity
WO2025085889A1 (en) * 2023-10-20 2025-04-24 Corvus Pharmaceuticals, Inc. Interleukin-2-inducible t-cell kinase inhibitors to produce enhanced immune responses
WO2025171035A1 (en) * 2024-02-06 2025-08-14 Corvus Pharmaceuticals, Inc. Itk inhibitors and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002050071A1 (en) * 2000-12-21 2002-06-27 Bristol-Myers Squibb Company Thiazolyl inhibitors of tec family tyrosine kinases
CA2458375A1 (en) 2001-08-24 2003-03-06 Pharmacia & Upjohn Company Substituted-heteroaryl-7-aza¬2.2.1|bicycloheptanes for the treatment of disease
ZA200602755B (en) * 2003-09-06 2007-06-27 Vertex Pharma Modulators of ATP-binding cassette transporters
EP2170852A1 (en) * 2007-06-11 2010-04-07 Bristol-Myers Squibb Company 1, 3 - dihydroxy substituted phenylamide glucokinase activators
US20100113520A1 (en) 2008-11-05 2010-05-06 Principia Biopharma, Inc. Kinase knockdown via electrophilically enhanced inhibitors
WO2011079231A1 (en) 2009-12-23 2011-06-30 Gatekeeper Pharmaceutical, Inc. Compounds that modulate egfr activity and methods for treating or preventing conditions therewith
US9649313B2 (en) 2012-11-26 2017-05-16 The University Of North Carolina At Chapel Hill Use of ITK inhibitors for the treatment of cancer
WO2014117292A1 (zh) * 2013-01-31 2014-08-07 中国科学院上海药物研究所 酰胺类化合物及其制备方法、药物组合物和用途
EP3715346B1 (en) 2014-10-22 2024-01-03 Dana-Farber Cancer Institute, Inc. Thiazolyl-containing compounds for treating proliferative diseases
WO2016079231A1 (en) 2014-11-19 2016-05-26 Hach Lange Gmbh Control of wastewater treatment based on regulatory period
CN105884711A (zh) * 2014-12-16 2016-08-24 中国药科大学 噻唑类化合物、其制备方法及其在制药中的用途
AU2016319125B2 (en) * 2015-09-09 2021-04-08 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
IL266181B2 (en) * 2016-11-03 2024-04-01 Corvus Pharmaceuticals Inc Compounds and methods for modulating interleukin-2-inducible t-cell kinase

Similar Documents

Publication Publication Date Title
JP2019536763A5 (https=)
JP2019524883A5 (https=)
JP2023530231A5 (https=)
JP2021519337A5 (https=)
JP2020533280A5 (https=)
RU2019105534A (ru) Модуляторы хемокинового рецептора и их применение
JP2022504949A5 (https=)
JP2022507020A5 (https=)
JP2016534148A5 (https=)
JP2014193925A5 (https=)
JP2009536650A5 (https=)
JP2018516238A5 (https=)
JP2019535759A5 (https=)
RU2016143333A (ru) Амидные производные и их фармацевтически приемлемые соли, способ их получения и медицинское применение
JP2016520131A5 (https=)
JP2005513125A5 (https=)
JP2017523143A5 (https=)
JP2018536681A5 (https=)
JP2009530410A5 (https=)
RU2016118753A (ru) Производные пиридилкетона, способ их получения и их фармацевтическое применение
RU2001116594A (ru) Пестициды
JP2018518518A5 (https=)
JP2020507566A5 (https=)
JP2014514290A5 (https=)
JP2019531346A5 (https=)